Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

ginkgo bioworks holdings inc - DNA

DNA

Close Chg Chg %
11.28 1.08 9.56%

Closed Market

12.36

+1.08 (9.56%)

Volume: 3.20M

Last Updated:

Nov 9, 2026, 3:59 PM EDT

Trade Now

Company Overview: ginkgo bioworks holdings inc - DNA

DNA Key Data

Open

$11.17

 Day Range

11.06 - 13.12

52 Week Range

5.37 - 18.22

 Market Cap

$640.83M

Shares Outstanding

64.34M

 Public Float

49.11M

Beta

1.75

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.63

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.53M

  

DNA Performance

1 Week
 
 0.71%
 
1 Month
 
 -13.15%
 
3 Months
 
 41.66%
 
1 Year
 
 26.15%
 
5 Years
 
 -97.81%
 

DNA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About ginkgo bioworks holdings inc - DNA

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

DNA At a Glance

Ginkgo Bioworks Holdings, Inc.
27 Drydock Avenue
Boston, Massachusetts 02210
Phone 1-877-422-5362 Revenue 170.16M
Industry Medical/Nursing Services Net Income -312,763,000.00
Sector Health Services Employees 485
Fiscal Year-end 12 / 2026
View SEC Filings

DNA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.708
Price to Book Ratio 0.902
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.847
Enterprise Value to Sales 2.769
Total Debt to Enterprise Value 0.934

DNA Efficiency

Revenue/Employee 350,835.052
Income Per Employee -644,872.165
Receivables Turnover 7.015
Total Asset Turnover 0.136

DNA Liquidity

Current Ratio 4.917
Quick Ratio 4.917
Cash Ratio 4.477

DNA Profitability

Gross Margin 48.716
Operating Margin -184.602
Pretax Margin -184.303
Net Margin -183.811
Return on Assets -25.05
Return on Equity -51.078
Return on Total Capital -32.975
Return on Invested Capital -30.066

DNA Capital Structure

Total Debt to Total Equity 86.491
Total Debt to Total Capital 46.378
Total Debt to Total Assets 39.286
Long-Term Debt to Equity 82.007
Long-Term Debt to Total Capital 43.974
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ginkgo Bioworks Holdings Inc - DNA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
477.71M 251.46M 227.04M 170.16M
Sales Growth
+52.21% -47.36% -9.71% -25.06%
Cost of Goods Sold (COGS) incl D&A
265.85M 108.81M 89.57M 87.26M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
61.63M 71.55M 63.02M 58.99M
Depreciation
56.03M 55.85M 45.02M 40.29M
Amortization of Intangibles
5.60M 15.70M 18.00M 18.70M
COGS Growth
+83.86% -59.07% -17.69% -2.57%
Gross Income
211.86M 142.64M 137.47M 82.89M
Gross Income Growth
+25.18% -32.67% -3.62% -39.70%
Gross Profit Margin
+44.35% +56.73% +60.55% +48.72%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.37B 814.87M 597.77M 397.00M
Research & Development
1.05B 525.81M 359.25M 203.48M
Other SG&A
1.32B 289.06M 238.53M 193.52M
SGA Growth
+18.86% -65.67% -26.64% -33.59%
Other Operating Expense
- - - -
-
Unusual Expense
(77.94M) 187.01M 114.61M 9.18M
EBIT after Unusual Expense
(2.08B) (859.24M) (574.91M) (323.29M)
Non Operating Income/Expense
(37.31M) (33.61M) 27.50M 9.69M
Non-Operating Interest Income
20.26M 57.22M 38.61M 22.62M
Equity in Earnings of Affiliates
- - (43.76M) (2.63M)
-
Interest Expense
- 106.00K 93.00K 94.00K
Interest Expense Growth
- -95.53% -12.26% +1.08%
Gross Interest Expense
- 106.00K 93.00K 94.00K
Interest Capitalized
- - - -
-
Pretax Income
(2.12B) (892.94M) (547.51M) (313.60M)
Pretax Income Growth
-15.41% +57.91% +38.68% +42.72%
Pretax Margin
-444.08% -355.11% -241.15% -184.30%
Income Tax
(15.03M) (71.00K) (479.00K) (837.00K)
Income Tax - Current - Domestic
271.00K 690.00K 566.00K 873.00K
Income Tax - Current - Foreign
159.00K 123.00K (109.00K) (346.00K)
Income Tax - Deferred - Domestic
- - - (14.44M)
-
Income Tax - Deferred - Foreign
(1.01M) (884.00K) (936.00K) (1.36M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - (43.76M) (2.63M)
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(2.11B) (892.87M) (547.03M) (312.76M)
Minority Interest Expense
- - - (1.44M)
-
Net Income
(2.10B) (892.87M) (547.03M) (312.76M)
Net Income Growth
-15.02% +57.58% +38.73% +42.83%
Net Margin Growth
-440.63% -355.08% -240.94% -183.81%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(2.10B) (892.87M) (547.03M) (312.76M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(2.10B) (892.87M) (547.03M) (312.76M)
EPS (Basic)
-50.1452 -18.368 -10.5412 -5.6397
EPS (Basic) Growth
-10.38% +63.37% +42.61% +46.50%
Basic Shares Outstanding
41.98M 48.61M 51.89M 55.46M
EPS (Diluted)
-50.1452 -18.368 -10.5412 -5.6397
EPS (Diluted) Growth
-6.96% +63.37% +42.61% +46.50%
Diluted Shares Outstanding
41.98M 48.61M 51.89M 55.46M
EBITDA
(2.10B) (600.68M) (397.28M) (255.12M)
EBITDA Growth
-16.76% +71.40% +33.86% +35.78%
EBITDA Margin
-439.66% -238.88% -174.98% -149.93%

Snapshot

Average Recommendation UNDERWEIGHT Average Target Price 7.00
Number of Ratings 3 Current Quarters Estimate -1.039
FY Report Date 12 / 2026 Current Year's Estimate -4.355
Last Quarter’s Earnings -0.64 Median PE on CY Estimate N/A
Year Ago Earnings -5.64 Next Fiscal Year Estimate -4.025
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 1 2 2
Mean Estimate -1.04 -1.41 -4.36 -4.03
High Estimates -0.82 -1.41 -3.55 -3.36
Low Estimate -1.26 -1.41 -5.16 -4.69
Coefficient of Variance -30.03 N/A -26.14 -23.37

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 1 0
OVERWEIGHT 0 0 0
HOLD 1 0 1
UNDERWEIGHT 0 0 0
SELL 2 2 1
MEAN Underweight Underweight Underweight

Insider Actions for Ginkgo Bioworks Holdings Inc - DNA

Date Name Shares Transaction Value
Oct 22, 2026 Jason Kelly See remarks; Director 174,747 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Bartholomew Canton See remarks; Director 375,132 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Bartholomew Canton See remarks; Director 365,370 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Bartholomew Canton 356,329 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.14 per share 3,613,176.06
Oct 22, 2026 Bartholomew Canton 375,132 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Bartholomew Canton 365,370 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Reshma Shetty 116,804 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Reshma Shetty 9,759 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Reshma Shetty See remarks; Director 116,804 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Reshma Shetty See remarks; Director 9,759 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Reshma Shetty 453,951 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.14 per share 4,603,063.14
Oct 22, 2026 Reshma Shetty 476,320 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Reshma Shetty 465,701 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Reshma Shetty See remarks; Director 453,951 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.14 per share 4,603,063.14
Oct 22, 2026 Reshma Shetty See remarks; Director 476,320 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Reshma Shetty See remarks; Director 465,701 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Jason Kelly See remarks; Director 283,677 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Jason Kelly See remarks; Director 18,564 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 22, 2026 Jason Kelly See remarks; Director 129,065 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.14 per share 1,308,719.10
Oct 22, 2026 Jason Kelly See remarks; Director 148,957 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Ginkgo Bioworks Holdings Inc in the News